Ultrastaging of Early Colon Cancer
- Determine whether the immunohistochemical and molecular presence of micrometastases in
≥ 12 lymph nodes removed during en-bloc resection in patients with stage II colon
cancer correlates with 3-year disease-free survival.
- Evaluate the prognostic significance of molecular markers detected in the primary tumor
and develop a microarray-based gene signature for stage II colon cancer.
OUTLINE: This is a multicenter study.
Tumor tissue and regional lymph node samples are collected during surgery for analysis of
micrometastases and molecular markers by immunohistochemistry, qRT-PCR, MM qRT-PCR,
qRDNA-PCR, and microarray profiling.
Patients are followed up periodically for 4 years after surgery.
Primary Purpose: Diagnostic
Disease-free survival (time to local or distant recurrence after resection)
Anton J. Bilchik, MD, PhD, FACS
Jonsson Comprehensive Cancer Center
|Walter Reed Army Medical Center||Washington, District of Columbia 20307-5000|
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|